MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 558176 | Name: Ferumoxytol
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ferumoxytol is an intravenous iron preparation for treatment of the anemia of chronic kidney disease (CKD).

Chemical Structure

Ferumoxytol
Ferumoxytol
CAS#1309-38-2

Theoretical Analysis

MedKoo Cat#: 558176

Name: Ferumoxytol

CAS#: 1309-38-2

Chemical Formula: Fe3O4

Exact Mass: 231.7800

Molecular Weight: 231.53

Elemental Analysis: Fe, 72.36; O, 27.64

Price and Availability

Size Price Availability Quantity
1g USD 150.00 Ready to ship
2g USD 250.00 Ready to ship
5g USD 450.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Ferumoxytol; Magnetic Black; Magnetic oxide; 11557 Black; Black Gold F 89; Black Iron BM;
IUPAC/Chemical Name
iron(II) diiron(III) oxide
InChi Key
SZVJSHCCFOBDDC-UHFFFAOYSA-N
InChi Code
InChI=1S/3Fe.4O
SMILES Code
O=[Fe]O[Fe]O[Fe]=O
Appearance
Solid powder
Purity
powder, <5 μm, 95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#S20G09M08
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Ferumoxytol is a superparamagnetic iron oxide nanoparticle that generates T1 relaxation and enhances T2 relaxation,
In vitro activity:
It has been reported that FMT induces a phenotypic shift in M2 macrophages towards a high CD86+, TNF-α positive M1 macrophage subtype. Since there are a large number of MDSCs that can take up FMT, it was hypothesized that FMT may alter the function of MDSCs. First, the cytotoxic effects of FMT at 250, 500, 1000, and 2000 μg/mL on MDSCs were evaluated by the CCK8 cell viability assay. The results showed that FMT had no effect on cell viability at low doses and only exhibited moderate cytotoxicity at the maximum dose of 2000 μg/mL (Fig.2a). It was then tested whether FMT at different concentrations would affect the generation of MDSCs. Bone marrow cells isolated from naïve C57BL/6 mice were treated with medium or various concentrations of FMT (250, 500, 1000, and 2000 μg/mL) for 4 days, followed by characterization by flow cytometry on day 4. GM-CSF and IL-6 were added on day 0. The results of three independent experiments revealed that FMT at 1000 and 2000 μg/mL significantly decreased the expansion of MDSCs (Fig,2b, c). Reference: Nanoscale Res Lett. 2019; 14: 379. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915194/
In vivo activity:
The effect of ferumoxytol was tested, and standard of care drug for AML, cytarabine (Ara-C) was used as a control. C57BL/6 female mice were transplanted with leukemic cells bearing BCR-ABL (GFP)/NUP98-HOXA9 (YFP) oncogenes. Cohorts were administered either saline, Ara-C (40 mg/kg), or ferumoxytol low at 3 mg/kg or high at 6 mg/kg. Ara-C was administered by intraperitoneal injection (IP) and saline and ferumoxytol were administered intravenously (IV) twice a week as indicated in Fig. 2a. In comparison with saline control group there was a significant reduction of the percentage of leukemic blasts populations in PB, BM, and SPL of mice only treated with ferumoxytol 6 mg/kg (Fig. 2b-e). We found the SPL weight of animals treated with ferumoxytol 6 mg/kg was overall lower as shown by the lower SPL index (spleen weight /total body weight) (Fig. 2f), indicating decreased disease burden. These data demonstrate that ferumoxytol at 6 mg/kg was able to induce an anti-leukemic effect in PB, BM, and SPL. Next, the effect of ferumoxytol in overall survival of the mice was evaluated via IP. Mice were treated with saline or ferumoxytol at 6 mg/kg three times a week, monitoring PB burden weekly until death (Fig 2g). Ferumoxytol clearly and significantly reduced the leukemic blast burden through 21 days in PB (Fig. 2h) and had a significant increase in median survival time (25 days ferumoxytol 6mg/kg, 17 days saline) (Fig. 2i). These findings demonstrate an anti-leukaemia effect with ferumoxytol administration alone and prolonged overall survival. Reference: Nat Nanotechnol. 2019 Jun; 14(6): 616–622. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554053/
Solvent mg/mL mM
Solubility
DMSO 0.0 0.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 231.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Trujillo-Alonso V, Pratt EC, Zong H, Lara-Martinez A, Kaittanis C, Rabie MO, Longo V, Becker MW, Roboz GJ, Grimm J, Guzman ML. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nat Nanotechnol. 2019 Jun;14(6):616-622. doi: 10.1038/s41565-019-0406-1. Epub 2019 Mar 25. PMID: 30911166; PMCID: PMC6554053. 2. Xu Y, Xue Y, Liu X, Li Y, Liang H, Dou H, Hou Y. Ferumoxytol Attenuates the Function of MDSCs to Ameliorate LPS-Induced Immunosuppression in Sepsis. Nanoscale Res Lett. 2019 Dec 16;14(1):379. doi: 10.1186/s11671-019-3209-2. PMID: 31844996; PMCID: PMC6915194.
In vitro protocol:
1. Trujillo-Alonso V, Pratt EC, Zong H, Lara-Martinez A, Kaittanis C, Rabie MO, Longo V, Becker MW, Roboz GJ, Grimm J, Guzman ML. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nat Nanotechnol. 2019 Jun;14(6):616-622. doi: 10.1038/s41565-019-0406-1. Epub 2019 Mar 25. PMID: 30911166; PMCID: PMC6554053. 2. Xu Y, Xue Y, Liu X, Li Y, Liang H, Dou H, Hou Y. Ferumoxytol Attenuates the Function of MDSCs to Ameliorate LPS-Induced Immunosuppression in Sepsis. Nanoscale Res Lett. 2019 Dec 16;14(1):379. doi: 10.1186/s11671-019-3209-2. PMID: 31844996; PMCID: PMC6915194.
In vivo protocol:
1. Trujillo-Alonso V, Pratt EC, Zong H, Lara-Martinez A, Kaittanis C, Rabie MO, Longo V, Becker MW, Roboz GJ, Grimm J, Guzman ML. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nat Nanotechnol. 2019 Jun;14(6):616-622. doi: 10.1038/s41565-019-0406-1. Epub 2019 Mar 25. PMID: 30911166; PMCID: PMC6554053. 2. Xu Y, Xue Y, Liu X, Li Y, Liang H, Dou H, Hou Y. Ferumoxytol Attenuates the Function of MDSCs to Ameliorate LPS-Induced Immunosuppression in Sepsis. Nanoscale Res Lett. 2019 Dec 16;14(1):379. doi: 10.1186/s11671-019-3209-2. PMID: 31844996; PMCID: PMC6915194.
1: Trong VM, Tuan VM, Chinh NT, Giang NV, Trang NT, Thanh DT, Hang TT, Hoang T. Characterization of Fly Ash Modified with Vinyltriethoxysilane. J Nanosci Nanotechnol. 2015 Aug;15(8):5905-9. PubMed PMID: 26369170. 2: Chao YC, Su SK, Lin YW, Hsu WT, Huang KS. Interfacial Properties of Polyethylene Glycol/Vinyltriethoxysilane (PEG/VTES) Copolymers and their Application to Stain Resistance. J Surfactants Deterg. 2012 May;15(3):299-305. Epub 2011 Nov 1. PubMed PMID: 22593640; PubMed Central PMCID: PMC3338328. 3: Vollet DR, Awano CM, de Vicente FS, Ruiz AI, Donatti DA. Temperature effect on the structure and formation kinetics of vinyltriethoxysilane-derived organic/silica hybrids. Langmuir. 2011 Sep 6;27(17):10986-92. doi: 10.1021/la200978y. Epub 2011 Jul 28. PubMed PMID: 21736335. 4: Nair BP, Pavithran C. Bifunctionalized hybrid silica spheres by hydrolytic cocondensation of 3-aminopropyltriethoxysilane and vinyltriethoxysilane. Langmuir. 2010 Jan 19;26(2):730-5. doi: 10.1021/la902432r. PubMed PMID: 19810713. 5: Li YS, Wright PB, Puritt R, Tran T. Vibrational spectroscopic studies of vinyltriethoxysilane sol-gel and its coating. Spectrochim Acta A Mol Biomol Spectrosc. 2004 Oct;60(12):2759-66. PubMed PMID: 15350910. 6: Ma Y, Zhou Q, Li A, Shuang C, Shi Q, Zhang M. Preparation of a novel magnetic microporous adsorbent and its adsorption behavior of p-nitrophenol and chlorotetracycline. J Hazard Mater. 2014 Feb 15;266:84-93. doi: 10.1016/j.jhazmat.2013.12.015. Epub 2013 Dec 15. PubMed PMID: 24380891. 7: John Ł, Podgórska M, Nedelec JM, Cwynar-Zając Ł, Dzięgiel P. Strontium-doped organic-inorganic hybrids towards three-dimensional scaffolds for osteogenic cells. Mater Sci Eng C Mater Biol Appl. 2016 Nov 1;68:117-127. doi: 10.1016/j.msec.2016.05.105. Epub 2016 May 24. PubMed PMID: 27524003. 8: Guha A, Biswas N, Bhattacharjee K, Sahoo N, Kuotsu K. pH responsive cylindrical MSN for oral delivery of insulin-design, fabrication and evaluation. Drug Deliv. 2016 Nov;23(9):3552-3561. Epub 2016 Oct 17. PubMed PMID: 27540687. 9: Segat D, Tavano R, Donini M, Selvestrel F, Rio-Echevarria I, Rojnik M, Kocbek P, Kos J, Iratni S, Sheglmann D, Mancin F, Dusi S, Papini E. Proinflammatory effects of bare and PEGylated ORMOSIL-, PLGA- and SUV-NPs on monocytes and PMNs and their modulation by f-MLP. Nanomedicine (Lond). 2011 Aug;6(6):1027-46. doi: 10.2217/nnm.11.30. Epub 2011 Jun 6. PubMed PMID: 21644818. 10: Fink S. Some new methods for affixing sections to glass slides. I. Aqueous adhesives. Stain Technol. 1987 Jan;62(1):27-33. PubMed PMID: 3590235. 11: Lee C, Seo J, Kim J, Jeong J, Han H, Kim H, Kim Y. Polymer Nanodot-Hybridized Alkyl Silicon Oxide Nanostructures for Organic Memory Transistors with Outstanding High-Temperature Operation Stability. Sci Rep. 2016 Oct 5;6:33863. doi: 10.1038/srep33863. PubMed PMID: 27703187; PubMed Central PMCID: PMC5050446. 12: Hernández-Escolano M, Juan-Díaz MJ, Martínez-Ibáñez M, Suay J, Goñi I, Gurruchaga M. Synthesis of hybrid sol-gel materials and their biological evaluation with human mesenchymal stem cells. J Mater Sci Mater Med. 2013 Jun;24(6):1491-9. doi: 10.1007/s10856-013-4900-y. Epub 2013 Mar 9. PubMed PMID: 23475116. 13: Yang L, Wang L, Cui C, Lei J, Zhang J. Stöber strategy for synthesizing multifluorescent organosilica nanocrystals. Chem Commun (Camb). 2016 May 4;52(36):6154-7. doi: 10.1039/c6cc01917j. Epub 2016 Apr 14. PubMed PMID: 27075518. 14: Craig RG, Dootz ER. Effect of mixed silanes on the hydrolytic stability of composites. J Oral Rehabil. 1996 Nov;23(11):751-6. PubMed PMID: 8953479. 15: Patrushev YV, Sidelnikov VN. The properties of capillary columns with silica organic-inorganic MCM-41 type porous layer stationary phase. J Chromatogr A. 2014 May 23. pii: S0021-9673(14)00792-4. doi: 10.1016/j.chroma.2014.05.042. [Epub ahead of print] PubMed PMID: 24933621. 16: Lei R, Wang H, Zuo YM. [Synthesis and evaluation of ethylstyrene-divinylbenzene-coated titania for high performance liquid chromatography]. Se Pu. 2001 Nov;19(6):516-9. Chinese. PubMed PMID: 12545462. 17: Kato K, Gong Y, Saito T, Yokogawa Y. Preparation and catalytic performance of lipases encapsulated in sol-gel materials. Biosci Biotechnol Biochem. 2002 Jan;66(1):221-3. PubMed PMID: 11866115. 18: Li H, Chen Y, Zeng Z, Xie C, Yang X. p-tert-Butylcalix[4]arene-1,3-bis(allyloxyethoxy)ether coated capillaries for open-tubular electrochromatography. Anal Sci. 2005 Jun;21(6):717-20. PubMed PMID: 15984214. 19: Tulumello D, Cooper G, Koprinarov I, Hitchcock AP, Rightor EG, Mitchell GE, Rozeveld S, Meyers GF, Stokich TM. Inner-shell excitation spectroscopy and X-ray photoemission electron microscopy of adhesion promoters. J Phys Chem B. 2005 Apr 7;109(13):6343-54. PubMed PMID: 16851707. 20: Biradar AV, Biradar AA, Asefa T. Silica-dendrimer core-shell microspheres with encapsulated ultrasmall palladium nanoparticles: efficient and easily recyclable heterogeneous nanocatalysts. Langmuir. 2011 Dec 6;27(23):14408-18. doi: 10.1021/la203066d. Epub 2011 Nov 8. PubMed PMID: 21951192. 1: Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2014 Apr;9(4):705-12. doi: 10.2215/CJN.05320513. Epub 2014 Jan 23. PubMed PMID: 24458078; PubMed Central PMCID: PMC3974353. 2: Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging. 2015 Apr;41(4):884-98. doi: 10.1002/jmri.24691. Epub 2014 Jun 30. Review. PubMed PMID: 24974785. 3: Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol. 2014 Jun;89(6):646-50. doi: 10.1002/ajh.23712. PubMed PMID: 24639149; PubMed Central PMCID: PMC4225478. 4: Schiller B, Bhat P, Sharma A. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther. 2014 Jan 1;36(1):70-83. doi: 10.1016/j.clinthera.2013.09.028. Epub 2013 Dec 7. PubMed PMID: 24315802. 5: Turkbey B, Agarwal HK, Shih J, Bernardo M, McKinney YL, Daar D, Griffiths GL, Sankineni S, Johnson L, Grant KB, Weaver J, Rais-Bahrami S, Harisinghani M, Jacobs P, Dahut W, Merino MJ, Pinto PA, Choyke PL. A Phase I Dosing Study of Ferumoxytol for MR Lymphography at 3 T in Patients With Prostate Cancer. AJR Am J Roentgenol. 2015 Jul;205(1):64-9. doi: 10.2214/AJR.14.13009. PubMed PMID: 26102381. 6: Vadhan-Raj S, Strauss W, Ford D, Bernard K, Boccia R, Li J, Allen LF. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol. 2014 Jan;89(1):7-12. doi: 10.1002/ajh.23582. Epub 2013 Sep 30. PubMed PMID: 23983177; PubMed Central PMCID: PMC4223995. 7: Ruangwattanapaisarn N, Hsiao A, Vasanawala SS. Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children. Pediatr Radiol. 2015 Jun;45(6):831-9. doi: 10.1007/s00247-014-3226-3. Epub 2014 Nov 27. PubMed PMID: 25427433; PubMed Central PMCID: PMC4446254. 8: Finn JP, Nguyen KL, Han F, Zhou Z, Salusky I, Ayad I, Hu P. Cardiovascular MRI with ferumoxytol. Clin Radiol. 2016 Aug;71(8):796-806. doi: 10.1016/j.crad.2016.03.020. Epub 2016 May 21. Review. PubMed PMID: 27221526. 9: Plock N, Facius A, Lahu G, Wood N, Frigo T, Deveney A, Aceves P. Population pharmacokinetic meta-analysis to bridge ferumoxytol plasma pharmacokinetics across populations. Clin Pharmacokinet. 2015 Apr;54(4):385-95. doi: 10.1007/s40262-014-0203-9. PubMed PMID: 25370033; PubMed Central PMCID: PMC4368844. 10: Hope MD, Hope TA, Zhu C, Faraji F, Haraldsson H, Ordovas KG, Saloner D. Vascular Imaging With Ferumoxytol as a Contrast Agent. AJR Am J Roentgenol. 2015 Sep;205(3):W366-73. doi: 10.2214/AJR.15.14534. Epub 2015 Jun 23. PubMed PMID: 26102308; PubMed Central PMCID: PMC5130335. 11: McConnell HL, Schwartz DL, Richardson BE, Woltjer RL, Muldoon LL, Neuwelt EA. Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific. Nanomedicine. 2016 Aug;12(6):1535-42. doi: 10.1016/j.nano.2016.03.009. Epub 2016 Apr 9. PubMed PMID: 27071335; PubMed Central PMCID: PMC4955720. 12: Cantow K, Pohlmann A, Flemming B, Ferrara F, Waiczies S, Grosenick D, Niendorf T, Seeliger E. Acute effects of ferumoxytol on regulation of renal hemodynamics and oxygenation. Sci Rep. 2016 Jul 20;6:29965. doi: 10.1038/srep29965. PubMed PMID: 27436132; PubMed Central PMCID: PMC4951703. 13: Chalouhi N, Jabbour P, Magnotta V, Hasan D. The emerging role of ferumoxytol-enhanced MRI in the management of cerebrovascular lesions. Molecules. 2013 Aug 13;18(8):9670-83. doi: 10.3390/molecules18089670. Review. PubMed PMID: 23945642. 14: Nayak AB, Luhar A, Hanudel M, Gales B, Hall TR, Finn JP, Salusky IB, Zaritsky J. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. Pediatr Nephrol. 2015 Mar;30(3):515-21. doi: 10.1007/s00467-014-2953-x. Epub 2014 Sep 12. PubMed PMID: 25212105; PubMed Central PMCID: PMC5911924. 15: Budjan J, Neudecker S, Schock-Kusch D, Kraenzlin B, Schoenberg SO, Michaely HJ, Attenberger UI. Can Ferumoxytol be Used as a Contrast Agent to Differentiate Between Acute and Chronic Inflammatory Kidney Disease?: Feasibility Study in a Rat Model. Invest Radiol. 2016 Feb;51(2):100-5. doi: 10.1097/RLI.0000000000000209. PubMed PMID: 26352750. 16: Toblli JE, Cao G, Giani JF, Dominici FP, Angerosa M. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model. Drug Res (Stuttg). 2015 Jul;65(7):354-60. doi: 10.1055/s-0034-1384534. Epub 2014 Jul 22. PubMed PMID: 25050519. 17: Khurana A, Nejadnik H, Chapelin F, Lenkov O, Gawande R, Lee S, Gupta SN, Aflakian N, Derugin N, Messing S, Lin G, Lue TF, Pisani L, Daldrup-Link HE. Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI. Nanomedicine (Lond). 2013 Dec;8(12):1969-83. doi: 10.2217/nnm.12.198. Epub 2013 Mar 27. PubMed PMID: 23534832; PubMed Central PMCID: PMC3816126. 18: Hedgire SS, McDermott S, Wojtkiewicz GR, Abtahi SM, Harisinghani M, Gaglia JL. Evaluation of renal quantitative T2* changes on MRI following administration of ferumoxytol as a T2* contrast agent. Int J Nanomedicine. 2014 Apr 28;9:2101-7. doi: 10.2147/IJN.S61460. eCollection 2014. PubMed PMID: 24812510; PubMed Central PMCID: PMC4010631. 19: Neiser S, Rentsch D, Dippon U, Kappler A, Weidler PG, Göttlicher J, Steininger R, Wilhelm M, Braitsch M, Funk F, Philipp E, Burckhardt S. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. Biometals. 2015 Aug;28(4):615-35. doi: 10.1007/s10534-015-9845-9. Epub 2015 Mar 24. PubMed PMID: 25801756. 20: Ferumoxytol: an intravenous iron, riskier than iron sucrose. Prescrire Int. 2013 Sep;22(141):206. PubMed PMID: 24171212.